abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
biotech · Advanced Solid Tumor · Sjogren's Disease · CGEM
Cullinan Therapeutics
Cullinan Therapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Dyer St, Providence, Rhode Island 02903, US HQ
2017 Founded
7 Employees
Public company Type
CGEM · NYSE Ticker
Company details
- Status
- Public
- HQ
- Dyer St, Providence, Rhode Island 02903, US
- Founded
- 2017
- Employees
- 7
- Programs
- 16
- Drugs
- 14
- Patents
- 3
Cullinan Therapeutics pipeline
Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Cullinan Therapeutics drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Interleukin-2 receptor.
- Target
- Interleukin-2 receptor
- Mechanism
- Interleukin-2 receptor agonist
-
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
- Target
- Phosphodiesterase 4
- Mechanism
- Phosphodiesterase 4 inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.
-
Development asset linked to Cullinan Therapeutics in public FDA and regional records.